Citi tells investors it’s time to sell Moderna after 600%-plus stock gains
- Moderna: 3 events in the last 90 days
- Previous: 7 days earlier · Merck and Moderna's cancer vaccine works. Making it affordable is the next test
What happened
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
Summary assembled by rule from the sources below